Market Overview

ISI Reiterates Buy, $120 PT On Biogen

Share:

International Strategy & Investment Group (ISI) reiterated a buy rating and $120 price target on biotech firm Biogen Idec (Nasdaq: BIIB) today. The price target implies only limited upside for the stock. The stock is up half a percent today.

Posted-In: Analyst Color News Price Target Reiteration Intraday Update Markets Analyst Ratings Trading Ideas

 

Related Articles (ISI + BIIB)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→